FLT3 and acute myeloid leukemia: A very recent study aimed at describing the mechanisms of early acquired resistance to FLT3 inhibitors showed that AML cells with FLT3-ITD mutations that persist after 48 h of FLT3 inhibitor drug exposure (drug-tolerant persisters) up-regulated both the inflammatory response gene and GR expression.